News Incyte builds GvHD presence with Niktimvo approval The FDA has approved Incyte's axatilimab as a treatment for chronic graft-versus-host disease (GvHD), making it a companion to the company's Jakafi for the disorder.
News Just how radical is the FDA's complete response letter move? The FDA says publishing complete response letters for medicines is an act of "radical transparency," but it is not as revolutionary as it seems.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face